CareRx (FRA:29C1) Moat Score: 3/10 (As of Aug. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:29C1 CareRx Corp FRA:29C1
66 GF Score
Price €2.04
GF Value €1.37
! 3 Warning Signs
View Full Analysis

What is CareRx Moat Score?

CareRx FRA:29C1 66 Moat Score is 3 as of Aug. 09, 2026. GuruFocus rates FRA:29C1 with a GF Score™ of 66/100 and a GF Value™ of €1.37. The stock has 3 warning signs investors should review. Among 669 Healthcare Providers & Services companies, CareRx ranks better than 84.45% on this metric.

CareRx has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

CareRx has No Moat: CareRx Corp has very weak competitive advantages with limited market leadership and customer loyalty. It lacks significant intellectual property, regulatory barriers, or cost advantages, resulting in a transient competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes CareRx might have No Moat - Very weak/transient advantages.

CareRx  (FRA:29C1) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

CareRx Moat Score Related Terms

FRA:29C1 vs HCA, THC, DVA: Moat Score Comparison

For the Medical Care Facilities subindustry, CareRx's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CareRx Moat Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, CareRx's Moat Score distribution charts can be found below:

* The bar in red indicates where CareRx's Moat Score falls into.


FRA:29C1
66GF Score
CareRx Corp FRA:29C1
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
CareRx (FRA:29C1) has a Moat Score of 3 as of Aug. 09, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, CareRx ranks #104 out of 669 companies in the Healthcare Providers & Services industry, placing it in the top 15.5%.
Is CareRx's Moat Score too high?
CareRx's current Moat Score is 3. Based on the distribution chart, CareRx ranks #104 out of 669 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, CareRx has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does CareRx's Moat Score compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, CareRx ranks #104 out of 669 companies for Moat Score. This places CareRx in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Healthcare Providers & Services company?
A good Moat Score depends on the Healthcare Providers & Services industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. CareRx's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CareRx stock overvalued right now?
CareRx (FRA:29C1) has a current Moat Score of 3. The stock's GF Value™ is €1.37, compared to a current price of €2.04 — trading 48.9% above its estimated fair value. The current Moat Score is 3. CareRx's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For CareRx (FRA:29C1), the current Moat Score is 3 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CareRx (FRA:29C1) Overvalued in 2026?

Based on GuruFocus' analysis, CareRx stock appears to be overvalued. The current stock price of €2.04 is trading 48.9% above its estimated GF Value™ of €1.37.

Key valuation signals for FRA:29C1:

  • Moat Score: 3
  • GF Value™: €1.37 vs. price of €2.04 (48.9% above fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the FRA:29C1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CareRx Business Description

Other Exchanges CHHHF:USACRRX:Canada
Address 320 Bay Street, Suite 1200, Toronto, ON, CAN, M5H 4A6
CareRx Corp is a provider of specialty pharmacy services to seniors. The company is a national organization with a large network of pharmacy fulfilment centers strategically located across the country. This allows it to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. It takes an active role in working with its home operator partners to promote resident health, staff education and medication system quality and efficiency. The Company has one reportable segment which consists of the Company-owned and operated institutional pharmacy business. Geographically it derives revenue from the sales of goods and capitated service fees in Ontario and Western Canada.
66GF Score

Get the complete analysis for FRA:29C1

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.04
Price
€1.37
GF Value